Recent Posts in ‘Biotech Stock Profiles’
ImmunoCellular (IMUC) Shareholder Update Validates Strong Potential for Growth
Biotechnology topics are hot in the investment community. Acquisitions are regularly being reported, new treatments are advancing in cancer therapy and stem cell research is being pursued down multiple avenues for its core competencies of repairing damaged body parts at the root of the problem. Bringing together these topics points to the direction of ImmunoCellular
Galectin Therapeutics (GALT): Three Franchises, One Big Opportunity
Galectin Therapeutics Inc. (OTCBB: GALT) is a leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins involved in progression or cause of disease. The promising role of galectin in cancer could give the company a distinct position with hopes of synergizing with other companies fighting cancer, from Dendreon Corporation (NASDAQ: DNDN) to Generex Biotechnology
ImmunoCellular (IMUC) Accelerating ICT-107 Clinical Trial Enrollment for Glioblastoma
Immunocellular Therapeutics Ltd. (OTCBB: IMUC) is a biopharmaceutical company focused on improving cancer treatments through new immune-based products. Unlike other cancer treatment companies, such as Dendreon (NASDAQ: DNDN), Oncothyreon (NASDAQ: ONTY) , IMUC is developing immunotherapies that target cancer stem cells in addition to normal cancer cells as a means to delay and prevent cancer
Amarantus (AMBS) CEO Gerald Commissiong Featured in Interview
Amarantus BioSciences Inc. (OTCBB: AMBS) is a biopharmaceutical company that has discovered a revolutionary therapeutic protein that could change the way many major diseases are treated. Unlike Insmed Inc. (NASDAQ:INSM) or Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), MANF works by reversing the properties of cell apoptosis, which has shown strong signs of efficacy in a wide
Cardium (CXM) Inks First Marketing & Distribution Agreement for Excellagen(TM)
Cardium Therapeutics (Amex: CXM), a developer and acquirer of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, similar to companies like Impax Laboratories Inc. (Nasdaq: IPXL) and Biogen Idec Inc. (Nasdaq: BIIB), recently entered into first marketing and distribution agreement
Amarantus (AMBS) Updates Shareholders on Expanded Corporate Strategy
Amarantus BioSciences Inc. (OTCBB: AMBS) is a biopharmaceutical company that has discovered a revolutionary therapeutic protein that could change the way many major diseases are treated. Unlike Insmed Inc. (NASDAQ:INSM) or Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), MANF works by reversing the properties of cell apoptosis, which has shown strong signs of efficacy in a wide
Cardium (CXM) and SourceOne Global Partners in Nutritional Supplement and Medical Foods Market
Cardium Therapeutics (NYSE Amex: CXM), a developer and acquirer of innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs and definable pathways to commercialization, like companies such as Nutraceutical International Corp (NASDAQ: NUTR) and Schiff Nutrition International Inc. (NYSE: WNI), recently partnered up with SourceOne via cross strategic investment
MabCure (MBCI): A Revolutionary Improvement to a Proven Cancer Technology
MabCure Inc. (PINK SHEETS: MBCI) is a biotechnology company focused on changing the perception that cancer is an incurable disease. Unlike Dendreon Corporation (NASDAQ: DNDN) or Generex Biotechnology Corporation (PINK SHEETS: GNBT), the company is developing monoclonal antibodies against tumor-specific antigens for diagnosis and treatment using its proprietary technology. Improving Upon a Classic Solution Hybridoma
500 Million or 1 in 10 Adults Will have Diabetes by 2030
ALR Technologies Inc. (OTCBB: ALRT), developer of the revolutionary Health-e-Connect system, operating in the telehealth industry alongside companies like American Medical Alert (NASDAQ: AMAC) and Verizon (NYSE: VZ), could dramatically change the way diabetes is treated by effectively monitoring people with diabetes at home. And given the growing instances of diabetes in our society, this
Cardium (CXM) Launches MedPodium Neo-Energy(TM) and Neo-Carb Bloc(TM)
Cardium Therapeutics (NYSE Amex: CXM), a developer and acquirer or new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, like companies such as Nutraceutical International Corp (NASDAQ: NUTR) and Schiff Nutrition International Inc. (NYSE: WNI), recently launched Neo-Energy™ and Neo-Carb Bloc™
Amarantus (AMBS) Appoints Seasoned Life Sciences Executive as Strategic Advisor
Amarantus BioSciences Inc. (OTCBB: AMBS) is a biopharmaceutical company that has discovered a revolutionary therapeutic protein that could change the way many major diseases are treated. Unlike Insmed Inc. (NASDAQ:INSM) or Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), MANF works by reversing the properties of cell apoptosis, which has shown strong signs of efficacy in a wide
Amarantus (AMBS) Leverages Partnerships to Deliver Value
Amarantus BioSciences Inc. (OTCBB: AMBS) is a biopharmaceutical company that has discovered a revolutionary therapeutic protein that could change the way many major diseases are treated. Unlike Insmed Inc. (NASDAQ:INSM) or Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), MANF works by reversing the properties of cell apoptosis, which has shown strong signs of efficacy in a wide